BioCentury | Feb 24, 2014
Finance

Microcap M&A

...$15 million in cash and a market cap of $16 million. In 2011, Mast acquired SynthRx Inc....
BioCentury | Feb 17, 2014
Regulation

Sickle cell suffering

...that Transcranial Doppler could show changes in cerebral circulation. Mast obtained MST-188 when it acquired SynthRx Inc....
BioCentury | May 16, 2011
Company News

Adventrx, CytRx deal

...shares in exchange for its 19.1% stake in SynthRx Inc. as part of Adventrx's acquisition of SynthRx...
...at $378,160, based on Adventrx's close of $2.32 on April 7, before its acquisition of SynthRx...
...for 20% of any shares paid to SynthRx shareholders under a 2003 deal, in which SynthRx...
BioCentury | Apr 18, 2011
Company News

Adventrx Pharmaceuticals Inc, SynthRx Inc. deal

...Adventrx completed its previously announced acquisition of SynthRx in a stock deal valued at up to...
...$37.8 million based on Adventrx's close of $2.32 on April 7, before the deal closed. SynthRx...
...candidate poloxamer 188 (see BioCentury, Feb. 21). Adventrx Pharmaceuticals Inc . (NYSE-A:ANX), San Diego, Calif. SynthRx Inc....
BioCentury | Feb 21, 2011
Company News

Adventrx, SynthRx Inc. deal

...Adventrx will acquire SynthRx in a stock deal valued at up to $35.5 million, based on...
...signed a non-binding term sheet to acquire an undisclosed private company in a stock deal. SynthRx...
...to SynthRx shareholders (see BioCentury, Oct. 27, 2003). Adventrx Pharmaceuticals Inc. (NYSE-A:ANX), San Diego, Calif. SynthRx Inc....
BioCentury | Oct 27, 2003
Company News

CytRx, SynthRx deal

...commercialize CYTR's co-polymer products, including Flocor and Opti-Vax. CYTR will receive a 19.9% stake in SynthRx...
...the deal will allow it to focus on RNAi. CytRx Corp. (CYTR), Los Angeles, Calif. SynthRx Inc....
Items per page:
1 - 6 of 6
BioCentury | Feb 24, 2014
Finance

Microcap M&A

...$15 million in cash and a market cap of $16 million. In 2011, Mast acquired SynthRx Inc....
BioCentury | Feb 17, 2014
Regulation

Sickle cell suffering

...that Transcranial Doppler could show changes in cerebral circulation. Mast obtained MST-188 when it acquired SynthRx Inc....
BioCentury | May 16, 2011
Company News

Adventrx, CytRx deal

...shares in exchange for its 19.1% stake in SynthRx Inc. as part of Adventrx's acquisition of SynthRx...
...at $378,160, based on Adventrx's close of $2.32 on April 7, before its acquisition of SynthRx...
...for 20% of any shares paid to SynthRx shareholders under a 2003 deal, in which SynthRx...
BioCentury | Apr 18, 2011
Company News

Adventrx Pharmaceuticals Inc, SynthRx Inc. deal

...Adventrx completed its previously announced acquisition of SynthRx in a stock deal valued at up to...
...$37.8 million based on Adventrx's close of $2.32 on April 7, before the deal closed. SynthRx...
...candidate poloxamer 188 (see BioCentury, Feb. 21). Adventrx Pharmaceuticals Inc . (NYSE-A:ANX), San Diego, Calif. SynthRx Inc....
BioCentury | Feb 21, 2011
Company News

Adventrx, SynthRx Inc. deal

...Adventrx will acquire SynthRx in a stock deal valued at up to $35.5 million, based on...
...signed a non-binding term sheet to acquire an undisclosed private company in a stock deal. SynthRx...
...to SynthRx shareholders (see BioCentury, Oct. 27, 2003). Adventrx Pharmaceuticals Inc. (NYSE-A:ANX), San Diego, Calif. SynthRx Inc....
BioCentury | Oct 27, 2003
Company News

CytRx, SynthRx deal

...commercialize CYTR's co-polymer products, including Flocor and Opti-Vax. CYTR will receive a 19.9% stake in SynthRx...
...the deal will allow it to focus on RNAi. CytRx Corp. (CYTR), Los Angeles, Calif. SynthRx Inc....
Items per page:
1 - 6 of 6